ASRT vs. TRVI, TNGX, BTMD, SNDL, CMRX, YMAB, VYGR, LFVN, ITOS, and AQST
Should you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Trevi Therapeutics (TRVI), Tango Therapeutics (TNGX), biote (BTMD), SNDL (SNDL), Chimerix (CMRX), Y-mAbs Therapeutics (YMAB), Voyager Therapeutics (VYGR), LifeVantage (LFVN), iTeos Therapeutics (ITOS), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.
Assertio vs.
Trevi Therapeutics (NASDAQ:TRVI) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.
Trevi Therapeutics currently has a consensus price target of $9.31, indicating a potential upside of 147.67%. Assertio has a consensus price target of $3.25, indicating a potential upside of 292.84%. Given Assertio's higher probable upside, analysts clearly believe Assertio is more favorable than Trevi Therapeutics.
Trevi Therapeutics has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Assertio has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 24.4% of Trevi Therapeutics shares are held by company insiders. Comparatively, 3.2% of Assertio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Trevi Therapeutics has higher earnings, but lower revenue than Assertio. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.
Assertio received 15 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. However, 65.52% of users gave Trevi Therapeutics an outperform vote while only 60.11% of users gave Assertio an outperform vote.
Trevi Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -54.46%. Assertio's return on equity of 3.79% beat Trevi Therapeutics' return on equity.
In the previous week, Trevi Therapeutics and Trevi Therapeutics both had 2 articles in the media. Trevi Therapeutics' average media sentiment score of 1.22 beat Assertio's score of 0.96 indicating that Trevi Therapeutics is being referred to more favorably in the media.
Summary
Trevi Therapeutics beats Assertio on 11 of the 16 factors compared between the two stocks.
Get Assertio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assertio Competitors List
Related Companies and Tools
This page (NASDAQ:ASRT) was last updated on 1/20/2025 by MarketBeat.com Staff
